CRTX — CRISM' Therapeutics Income Statement
0.000.00%
- £4.41m
- £1.02m
Annual income statement for CRISM' Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.98 | 3.19 | 1.79 | 2.6 | 2.26 |
Operating Profit | -1.98 | -3.19 | -1.79 | -2.6 | -2.26 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.33 | -2.67 | -1.79 | -2.6 | -2.39 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.33 | -2.67 | -1.79 | -2.6 | -2.39 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2.33 | -2.67 | -1.21 | -3.01 | -9.65 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.33 | -2.67 | -1.21 | -3.01 | -9.65 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.506 | -0.35 | -0.177 | -0.256 | -0.275 |
Special Dividends per Share |